NO872674L - Metastasehemmende middel. - Google Patents
Metastasehemmende middel.Info
- Publication number
- NO872674L NO872674L NO872674A NO872674A NO872674L NO 872674 L NO872674 L NO 872674L NO 872674 A NO872674 A NO 872674A NO 872674 A NO872674 A NO 872674A NO 872674 L NO872674 L NO 872674L
- Authority
- NO
- Norway
- Prior art keywords
- heparin
- per day
- approx
- mixture
- metastases
- Prior art date
Links
- 206010027476 Metastases Diseases 0.000 title claims description 19
- 239000003112 inhibitor Substances 0.000 title description 3
- 229920000669 heparin Polymers 0.000 claims description 36
- 229960002897 heparin Drugs 0.000 claims description 36
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 35
- 108010037536 heparanase Proteins 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 102100024025 Heparanase Human genes 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 230000009401 metastasis Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002628 heparin derivative Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 206010027458 Metastases to lung Diseases 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL79255A IL79255A0 (en) | 1986-06-26 | 1986-06-26 | Composition for metastasis prevention |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO872674D0 NO872674D0 (no) | 1987-06-25 |
| NO872674L true NO872674L (no) | 1987-12-28 |
Family
ID=11056897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO872674A NO872674L (no) | 1986-06-26 | 1987-06-25 | Metastasehemmende middel. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4882318A (de) |
| EP (1) | EP0254067A3 (de) |
| JP (1) | JPS6388128A (de) |
| AU (1) | AU7470587A (de) |
| DK (1) | DK331387A (de) |
| IL (1) | IL79255A0 (de) |
| NO (1) | NO872674L (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262403A (en) * | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
| US5206223A (en) * | 1986-06-26 | 1993-04-27 | Yeda Research And Development Co. Ltd. | Method for inhibiting heparanase activity |
| IL85145A (en) * | 1987-01-23 | 1994-08-26 | Univ Australian | Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity |
| US5541166A (en) * | 1987-01-23 | 1996-07-30 | The Australian National University | Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity |
| IL86753A0 (en) * | 1988-06-15 | 1988-11-30 | Hadassah Med Org | Pharmaceutical compositions for treatment of lupus |
| IL88554A0 (en) * | 1988-12-01 | 1989-07-31 | Hadassah Med Org | Compositions containing a compound binding to a heparin receptor |
| US5340932A (en) * | 1989-08-18 | 1994-08-23 | Ajorca S.A. | Substances with heparin-like structure and their method of production |
| US5362641A (en) * | 1989-08-23 | 1994-11-08 | Hadassah Medical Organization Kiryat Hadassah | Heparanase derived from human Sk-Hep-1 cell line |
| DK148890D0 (da) * | 1990-06-19 | 1990-06-19 | Novo Nordisk As | Farmaceutisk praeparat |
| US5733892A (en) * | 1990-07-24 | 1998-03-31 | Seikagaku Corporation | Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same |
| WO1992001720A1 (fr) * | 1990-07-24 | 1992-02-06 | Seikagaku Kogyo Kabushiki Kaisha | Glycosaminoglycane se combinant a un phospholipide ou a un lipide, production de ce compose et inhibiteur de metastase du cancer |
| US6060296A (en) * | 1991-07-03 | 2000-05-09 | The Salk Institute For Biological Studies | Protein kinases |
| US6750207B1 (en) * | 1992-05-01 | 2004-06-15 | Yeda Research And Development Co. Ltd. | Compositions for the regulation of cytokine activity |
| JPH08501456A (ja) * | 1993-07-06 | 1996-02-20 | エフ．ホフマン−ラ ロシュ アーゲー | ホルモン非依存性乳癌細胞特異的タンパク質のマンマモジュリン |
| FR2708198B1 (fr) * | 1993-07-28 | 1995-10-20 | Dior Christian Parfums | Composition cosmétique ou pharmaceutique, notamment dermatologique contenant un extrait de Tephrosia, en particulier Tephrosia purpurea. |
| US6440445B1 (en) | 1996-09-30 | 2002-08-27 | Brigham & Women's Hospital | Methods and compounds for treatment of abnormal uterine bleeding |
| US20020088019A1 (en) * | 1997-09-02 | 2002-07-04 | Oron Yacoby-Zeevi | Methods of and pharmaceutical compositions for improving implantation of embryos |
| US20030161823A1 (en) * | 1998-08-31 | 2003-08-28 | Neta Ilan | Therapeutic and cosmetic uses of heparanases |
| US6699672B1 (en) * | 1997-09-02 | 2004-03-02 | Insight Biopharmaceuticals Ltd. | Heparanase specific molecular probes and their use research and medical applications |
| US20040213789A1 (en) * | 1997-09-02 | 2004-10-28 | Oron Yacoby-Zeevi | Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies |
| US6190875B1 (en) * | 1997-09-02 | 2001-02-20 | Insight Strategy & Marketing Ltd. | Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| US6177545B1 (en) * | 1997-09-02 | 2001-01-23 | Insight Strategy & Marketing Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
| US20010006630A1 (en) * | 1997-09-02 | 2001-07-05 | Oron Yacoby-Zeevi | Introducing a biological material into a patient |
| AU2759199A (en) | 1998-02-24 | 1999-09-15 | Pharmacia & Upjohn Company | Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity |
| US20030217375A1 (en) * | 1998-08-31 | 2003-11-20 | Eyal Zcharia | Transgenic animals expressing heparanase and uses thereof |
| AU2878600A (en) * | 1999-03-01 | 2000-09-21 | Hadasit Medical Research Services & Development Company Ltd | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells |
| WO2001046392A2 (en) | 1999-12-22 | 2001-06-28 | Oxford Glycosciences (Uk) Ltd. | Homologues of human heparanase and splice variants thereof |
| US7781416B2 (en) | 2000-01-25 | 2010-08-24 | Sigma-Tau Research Switzerland S.A. | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
| US20020064853A1 (en) * | 2000-04-20 | 2002-05-30 | Heinrikson Robert Leroy | Heparanase II, a novel human heparanase paralog |
| CN1197587C (zh) * | 2000-06-09 | 2005-04-20 | 中国科学院上海细胞生物学研究所 | N－位脱硫酸肝素在预防和治疗炎症中的应用 |
| CZ307433B6 (cs) * | 2001-09-12 | 2018-08-22 | Leadiant Biosciences Sa | Deriváty částečně desulfátovaných glykosaminoglykanů jako inhibitory heparanázy mající antiangiogenní účinky a zabraňující antikoagulačnímu působení |
| US6671189B2 (en) * | 2001-11-09 | 2003-12-30 | Minebea Co., Ltd. | Power converter having primary and secondary side switches |
| US7285536B2 (en) * | 2001-12-05 | 2007-10-23 | Yeda Research And Development Co., Ltd. | Anti-cancer therapeutic compounds |
| US20060269552A1 (en) * | 2003-06-09 | 2006-11-30 | Oron Yacoby-Zeevi | Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies |
| WO2005076743A2 (en) * | 2004-02-17 | 2005-08-25 | Yeda Research And Development Co. Ltd. | Disaccharide molecules and derivatives thereof and methods of using same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR81305E (fr) * | 1959-01-29 | 1963-09-06 | Roussel Uclaf | Procédé de préparation de la nu-désulfo héparine et de ses dérivés acyles |
| DE3373782D1 (en) * | 1982-12-20 | 1987-10-29 | Harvard College | Inhibition of angiogenesis |
| GR79775B (de) * | 1983-03-22 | 1984-10-31 | Cegedur |
-
1986
- 1986-06-26 IL IL79255A patent/IL79255A0/xx unknown
-
1987
- 1987-06-24 US US07/067,582 patent/US4882318A/en not_active Expired - Fee Related
- 1987-06-25 NO NO872674A patent/NO872674L/no unknown
- 1987-06-25 AU AU74705/87A patent/AU7470587A/en not_active Abandoned
- 1987-06-25 EP EP87109142A patent/EP0254067A3/de not_active Withdrawn
- 1987-06-26 JP JP62159515A patent/JPS6388128A/ja active Pending
- 1987-06-26 DK DK331387A patent/DK331387A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6388128A (ja) | 1988-04-19 |
| US4882318A (en) | 1989-11-21 |
| IL79255A0 (en) | 1986-09-30 |
| EP0254067A3 (de) | 1988-09-14 |
| NO872674D0 (no) | 1987-06-25 |
| EP0254067A2 (de) | 1988-01-27 |
| AU7470587A (en) | 1988-01-07 |
| DK331387D0 (da) | 1987-06-26 |
| DK331387A (da) | 1987-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO872674L (no) | Metastasehemmende middel. | |
| Richardson et al. | Chemotherapy induced diarrhea | |
| Andoh et al. | Role of dietary fiber and short-chain fatty acids in the colon | |
| Grecomoro et al. | Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of osteoarthritis of the knee: a preliminary open study | |
| Schmitz et al. | β-Adrenergic blockade during systemic inflammation: impact on cellular immune functions and survival in a murine model of sepsis | |
| Gadangi et al. | The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites | |
| Maccagno et al. | Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout | |
| Chang et al. | Hyaluronan regulates PPARγ and inflammatory responses in IL-1β-stimulated human chondrosarcoma cells, a model for osteoarthritis | |
| Knight et al. | Use of Glucagon in the Treatment of Pancreatitis | |
| US20090137525A1 (en) | Glycosaminoglycan Composition and Method for Treatment and Prevention of Interstitial Cystitis | |
| Willenborg et al. | Inhibition of allergic encephalomyelitis in rats by treatment with sulfated polysaccharides. | |
| Bresnihan | Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist | |
| Gibbons et al. | Involvement of brain opioid receptors in the anti-allodynic effect of hyperbaric oxygen in rats with sciatic nerve crush-induced neuropathic pain | |
| JP2010529049A (ja) | ナリンゲニンとナリンジンを形質転換成長因子−β１のシグナル経路阻害剤とする使用 | |
| CN1157716A (zh) | 转移抑制剂 | |
| El-Haj et al. | Anorexia in a rat model of colitis: interaction of interleukin-1 and hypothalamic serotonin | |
| SK12502001A3 (sk) | Prostriedok na liečbu artritídy | |
| US20100317583A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa) | |
| Hoffmann et al. | Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34 | |
| DE3786456T2 (de) | Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen. | |
| Adlesic et al. | Histamine in rheumatoid arthritis | |
| Wang et al. | Myrislignan ameliorates the progression of osteoarthritis: An in vitro and in vivo study | |
| Thurman et al. | Effects of group B Streptococcus toxin on long-term survival of mice bearing transplanted Madison lung tumors | |
| EP0299975B1 (de) | Zubereitung zum stoppen von angiogenese und einem kapillar-, zellen- oder membranleck | |
| US6476002B1 (en) | Treatment of chronic inflammatory diseases with CM101/GBS toxin |